Products Suvorexant was approved in the United States in 2014 as the first agent in the orexin receptor antagonist group in the form of film-coated tablets (Belsomra). Structure and properties Suvorexant (C23H23ClN6O2, Mr = 450.9 g/mol) exists as a white powder that is insoluble in water. It is a benzoxazole, diazepane and triazole derivative. Effects … Suvorexant
Products Lemborexant was approved in the United States in 2019 in film-coated tablet form (Dayvigo). This as the second agent in the orexin receptor antagonist group. Structure and properties Lemborexant (C22H20F2N4O2, Mr = 410.42 g/mol) is a pyrimidine and pyridine derivative. It exists as a white powder and is practically insoluble in water. Effects Lemborexant … Lemborexant
Products Almorexant is not commercially available. Clinical development was discontinued by Actelion and GlaxoSmithKline (GSK) in 2011 due to adverse effects. Structure and properties Almorexant (C29H31F3N2O3, Mr = 512.6 g/mol) is a tetrahydroisoquinoline derivative. It is structurally related to the opioid methopholine. Effects Almorexant has sleep-inducing properties. It is a selective and dual antagonist at … Almorexant
